SoftOx Solutions AS (OSL:SOFTX)

Market Cap	284.16M +74.2%
Revenue (ttm)	16.27M +96.9%
Net Income	-17.87M
EPS	n/a
Shares Out	2.56B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,833,553
Open	0.1160
Previous Close	0.1078
Day's Range	0.1078 - 0.1160
52-Week Range	0.0490 - 0.1658
Beta	0.98
Analysts	n/a
Price Target	n/a
Earnings Date	May 27, 2026

About SoftOx Solutions AS

SoftOx Solutions AS, together with its subsidiaries, operates as a clinical-stage pharmaceutical company that anti-infective therapy for airway infections in Norway. The company develops SIS-03, a lead clinical program that is in phase 2a to treatment of chronic airway infections. It also developing pan antimicrobial pharmaceuticals targeting bacteria, viruses, yeast, spores, and fungi. SoftOx Solutions AS was founded in 2012 and is based in Lysaker, Norway.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 2
• Stock Exchange: Oslo Børs
• Ticker Symbol: SOFTX

Financial Performance

In 2025, SoftOx Solutions AS's revenue was 15.58 million, an increase of 96.92% compared to the previous year's 7.91 million. Losses were -10.81 million, -74.82% less than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 25, 2026

Data Sources Report a data error